Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 6, 2007

Roche to Commercialize ARK's Monitoring Tests for HIV Therapies

  • ARK Diagnostics and Roche Diagnostics signed a letter of intent to negotiate an agreement that would grant Roche distribution and commercialization rights to  ARK's anti-HIV drug monitoring products.

    ARK's tests include immunoassay reagents for certain classes of anti-HIV drugs such as protease inhibitors and nonnucleoside reverse transcriptase inhibitors used to suppress viral replication. The immunoassay reagents are compatible with most automated clinical chemistry analyzers and measure a patient's blood level of anti-HIV drug, according to the companies.

    “We are pleased to partner with Roche   to leverage its distribution and marketing strengths to quickly get the anti-HIV drug monitoring products to market,” states Johnny Valdez, president of ARK. “Roche will be immediately selling and distributing our products worldwide.”



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »